Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NUW0UHp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HjTGlEPTB;NT64OlY3KM7:TR?= NWPnOXVOW0GQR1XS
DOHH-2 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nFfmlEPTB;OT6zOVY5QSEQvF2= NH;RdolUSU6JRWK=
no-10 NX;3[45uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzhZoYzUUN3ME25MlkxOzlizszN MYDTRW5ITVJ?
LS-513 M{fjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nweGlEPTB;MUGuN|U1PyEQvF2= M17qdnNCVkeHUh?=
ALL-PO NU\ZcVNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPVTmZqUUN3ME2xNU44PzN2IN88US=> M3vtNHNCVkeHUh?=
8-MG-BA NFn3Z3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX64PYhtUUN3ME2xN{4yOTJ|IN88US=> NGfpcZJUSU6JRWK=
RPMI-8402 NILDPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;5TWM2OD1zNT64OVM4KM7:TR?= M3jLXnNCVkeHUh?=
EoL-1-cell M4fFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzEemQ{UUN3ME2xPE42QTR6IN88US=> NIj5ZVJUSU6JRWK=
NALM-6 MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\nTWM2OD1zOT6wNVY4KM7:TR?= NYPRbWE3W0GQR1XS
DEL M1TWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ZVohKSzVyPUKwMlE1PzFizszN MnHxV2FPT0WU
SR NUDyZ4ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\KZWo6UUN3ME2yN{43PzF3IN88US=> MX7TRW5ITVJ?
697 NVfuendzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTMTWM2OD1{Nj62NVU2KM7:TR?= M33Ee3NCVkeHUh?=
COLO-829 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;ueGlEPTB;Mk[uPFQ5OyEQvF2= M125cnNCVkeHUh?=
EVSA-T Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyxZVdnUUN3ME2yO{42PTZzIN88US=> NWDWV5g{W0GQR1XS
ATN-1 M1P6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjETWM2OD1|MT6yN|I6KM7:TR?= MnnrV2FPT0WU
L-363 M{P5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTNzLke0OlEh|ryP NVvjdI1DW0GQR1XS
LAMA-84 NETvc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vYbWlEPTB;M{KuOVIyOSEQvF2= MoDDV2FPT0WU
NOS-1 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnWyTWM2OD1|ND6yPVU3KM7:TR?= NWK1N4FDW0GQR1XS
BB30-HNC MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K0RmlEPTB;M{SuN|MxPiEQvF2= MW\TRW5ITVJ?
BC-1 M{PWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN5Lkm3OFYh|ryP Ml3jV2FPT0WU
IST-SL2 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[wTWM2OD1|OD6yNlQh|ryP MYnTRW5ITVJ?
D-392MG M33qeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknNTWM2OD12MD6yNlE2KM7:TR?= MUfTRW5ITVJ?
no-11 NEHnVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRyLkW1NlEh|ryP MknBV2FPT0WU
LC4-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm1TWM2OD12MD64O|E3KM7:TR?= MmnPV2FPT0WU
A388 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXHWYkyUUN3ME20Nk42QDR6IN88US=> M1rTc3NCVkeHUh?=
NTERA-S-cl-D1 M1S2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL1V4FKSzVyPUSyMlcxPzRizszN MUjTRW5ITVJ?
CESS NVrYXI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\TTGlEPTB;NESuNlI{OiEQvF2= NEnP[oZUSU6JRWK=
RS4-11 M3nLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR7LkC5N|gh|ryP NXnidoNtW0GQR1XS
MS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTVyLkmzOVEh|ryP MVzTRW5ITVJ?
CTV-1 NUDlOXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWy[ZQxUUN3ME21NU4xPzRizszN MnH4V2FPT0WU
D-502MG MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHrTWM2OD13MT62NlcyKM7:TR?= MVvTRW5ITVJ?
ML-2 NYfyd2k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S4SmlEPTB;NUKuPVE6PSEQvF2= NWX5d5I4W0GQR1XS
SK-NEP-1 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTV|LkO5NlMh|ryP M2DtPXNCVkeHUh?=
LOXIMVI NWf6b|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG3TWM2OD13Mz61PFg1KM7:TR?= NWPWc49{W0GQR1XS
DJM-1 M1XqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\UTmlEPTB;NU[uN|M6OSEQvF2= NITCVGZUSU6JRWK=
GI-1 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPNWXp[UUN3ME21Ok43OTR7IN88US=> MYHTRW5ITVJ?
IST-MES1 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tie2lEPTB;NkCuOVQ6OyEQvF2= M1LBNnNCVkeHUh?=
MV-4-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTZyLk[1N|gh|ryP Moj1V2FPT0WU
OVCAR-4 NGWwelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjxTWM2OD14Mz61OlU4KM7:TR?= MnPnV2FPT0WU
KE-37 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3yO2hKSzVyPU[2MlI3PjhizszN M3jHWXNCVkeHUh?=
D-542MG NVPmPWhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jFbGlEPTB;NkiuOFE{PSEQvF2= NYH1[Wh1W0GQR1XS
MHH-PREB-1 NIXXUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3nNZVKSzVyPUeyMlg1PDFizszN Mme4V2FPT0WU
MRK-nu-1 M1HNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLGTWM2OD15Mz60O|A2KM7:TR?= MnGwV2FPT0WU
D-247MG MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXHTpdKSzVyPUezMlU1PDJizszN MX\TRW5ITVJ?
OCI-AML2 NXTLNnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTd4LkmzOlkh|ryP M3jGTnNCVkeHUh?=
LP-1 M1Pac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf0ZoVKSzVyPUiyMlg4OzFizszN NIn1NoJUSU6JRWK=
HCC1599 NUjocotNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnS[VlKSzVyPUi0MlI5OzdizszN M2j5ZXNCVkeHUh?=
KARPAS-45 NUOxPYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XYRWlEPTB;OESuOlk6OiEQvF2= MnviV2FPT0WU
BE-13 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXPTWM2OD17OT6wOFc4KM7:TR?= NIjmSHdUSU6JRWK=
GCIY MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTl7LkC5OVQh|ryP MVXTRW5ITVJ?
BV-173 NWfxVG5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\ZdWhKSzVyPUGwNE4{OjVizszN NFHZbmZUSU6JRWK=
LB2518-MEL MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFyMD63PFkh|ryP NH;2b|ZUSU6JRWK=
KS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfWTHdKSzVyPUGwNU43OzlizszN Mn;LV2FPT0WU
MOLT-16 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDNmlEPTB;MUC0Mlk5PiEQvF2= NXPHUGJYW0GQR1XS
NCI-H1770 M2OzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfYOG5UUUN3ME2xNFgvPzh2IN88US=> NYDGVZNyW0GQR1XS
NCI-H82 M{\tU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HxbGlEPTB;MUGwMlk4PiEQvF2= NIf2dY9USU6JRWK=
NCCIT MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTSOGRKSzVyPUGxNk42OjlizszN NU\0XJh7W0GQR1XS
KALS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPMTWM2OD1zMUWuPVQyKM7:TR?= MV\TRW5ITVJ?
LB2241-RCC NHu4cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFzNj62O|kh|ryP MVfTRW5ITVJ?
HH M3zifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTpTWM2OD1zMUeuN|k2KM7:TR?= NET3NYJUSU6JRWK=
HD-MY-Z Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFzOD60PFgh|ryP NYX4eWJ4W0GQR1XS
EB-3 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF{Mz6wPVQh|ryP M{jONHNCVkeHUh?=
BL-70 NFnDNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES2O41KSzVyPUGyN{4yOjdizszN M{fY[XNCVkeHUh?=
K-562 NIThUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF{Nj6yOFUh|ryP MVjTRW5ITVJ?
HT-144 NYX5UWRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3UO5RKSzVyPUGzN{4yPjRizszN NEDJbVVUSU6JRWK=
PF-382 M1[xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF|ND6zOlEh|ryP Mny0V2FPT0WU
RPMI-8226 M4P1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK1TWM2OD1zM{WuNFQ2KM7:TR?= M3XLeHNCVkeHUh?=
NCI-H1355 NXzoSW1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF|NT61PFch|ryP MXnTRW5ITVJ?
LXF-289 M2j1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;Ke4xKSzVyPUGzPU44QDFizszN NInST2JUSU6JRWK=
NCI-H69 M3\RPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF2Mj65N|Ih|ryP MVvTRW5ITVJ?
SK-MEL-1 NVHKWI5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;JUIVKSzVyPUG0O{4yOyEQvF2= M17v[3NCVkeHUh?=
KARPAS-299 M4n1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iyfGlEPTB;MUS5MlEzKM7:TR?= MlnGV2FPT0WU
GB-1 M2LCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n4U2lEPTB;MUS5MlMzOiEQvF2= M4rXXHNCVkeHUh?=
CMK NGjDcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzHfJF3UUN3ME2xOFkvPTF3IN88US=> MYDTRW5ITVJ?
MPP-89 M1r5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP3SpRKSzVyPUG1Ok4xOzVizszN MV3TRW5ITVJ?
KU812 M2LjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfkUFdYUUN3ME2xOlEvQTB{IN88US=> MVLTRW5ITVJ?
REH NFq2bllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\IUII6UUN3ME2xOlIvOTJ3IN88US=> M1j4SHNCVkeHUh?=
NEC8 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;rTWM2OD1zNkWuNFI3KM7:TR?= MlXoV2FPT0WU
KP-N-YS M4XQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrZb2xKSzVyPUG2PE4{QTVizszN M{jp[nNCVkeHUh?=
Ramos-2G6-4C10 NHTjRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\mV2lEPTB;MU[5MlkyPSEQvF2= NHP1em5USU6JRWK=
Becker MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITWV4xKSzVyPUG3OE4yQCEQvF2= MmTLV2FPT0WU
LB647-SCLC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LHRWlEPTB;MUe1Mlg1PSEQvF2= NI\Ue3JUSU6JRWK=
LU-139 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfZTWM2OD1zN{iuNFE6KM7:TR?= NEO5bpVUSU6JRWK=
QIMR-WIL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF5OT62OFYh|ryP NYn2WJJPW0GQR1XS
NCI-H1395 NEHJc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K5TGlEPTB;MUe5Mlk6PiEQvF2= NYTpUlFpW0GQR1XS
NOMO-1 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF70TWZKSzVyPUG4Nk45PSEQvF2= NILDXI9USU6JRWK=
GI-ME-N MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\6RVNDUUN3ME2xPFcvQTZ7IN88US=> MW\TRW5ITVJ?
KMS-12-PE NYO1ZmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHYNYUyUUN3ME2xPFkvOjd|IN88US=> M{TwNHNCVkeHUh?=
Daudi NEm0NlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXETWM2OD1zOUGuNVI5KM7:TR?= Mm\UV2FPT0WU
LB996-RCC NWTmZ4xrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvlW5pKSzVyPUG5NU43QTlizszN NI\BV4RUSU6JRWK=
NCI-H2107 M{XxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrmXYF1UUN3ME2xPVMvPzN7IN88US=> M3u1THNCVkeHUh?=
SK-PN-DW MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfZSJJGUUN3ME2xPVQvPzF7IN88US=> MknYV2FPT0WU
MC-CAR MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13PV2lEPTB;MkCyMlI2OyEQvF2= M2TufXNCVkeHUh?=
SNB75 NHe5PHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrtTWM2OD1{MkGuPVQh|ryP NEG3RnBUSU6JRWK=
ES4 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ{Mz63PFMh|ryP MVnTRW5ITVJ?
KARPAS-422 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofPTWM2OD1{MkiuN|UzKM7:TR?= NGXqVZRUSU6JRWK=
NCI-H1648 NGTiWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjFTWM2OD1{MkmuOFg6KM7:TR?= MmXQV2FPT0WU
ES6 NVPhZ5RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWOwTlA3UUN3ME2yN|kvPDNizszN NHXHeXBUSU6JRWK=
KNS-81-FD MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\v[nU6UUN3ME2yOFEvOTl5IN88US=> MXPTRW5ITVJ?
JAR NFfkcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXCcYVlUUN3ME2yOVYvOjJ3IN88US=> MkPtV2FPT0WU
NB1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ4MD61NVYh|ryP MkTaV2FPT0WU
D-336MG M{fQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DPRmlEPTB;Mk[wMlY6QCEQvF2= NF7reJJUSU6JRWK=
BC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TtOGlEPTB;Mk[1MlE4QCEQvF2= MWjTRW5ITVJ?
HCC2218 M3f0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPvTWM2OD1{Nk[uOFE2KM7:TR?= NVzxcFhwW0GQR1XS
TE-9 NWT4[VF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ4Nj62Nlch|ryP MlTnV2FPT0WU
LB1047-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHqfINKSzVyPUK2Ok44PTNizszN M4TE[3NCVkeHUh?=
CTB-1 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJ4OT65O|Mh|ryP M2TLZXNCVkeHUh?=
NB7 NVv4R4g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof4TWM2OD1{N{Gg{txO MXnTRW5ITVJ?
ST486 NHnkV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXBVmtKSzVyPUK3O{41OTJizszN MUnTRW5ITVJ?
HCC1187 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLYTWM2OD1{OEKuPFEyKM7:TR?= M{PkOXNCVkeHUh?=
NCI-SNU-16 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ6ND6yOFgh|ryP M3TOWHNCVkeHUh?=
COR-L279 NV:w[pduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPHPWRmUUN3ME2yPVEvPTh2IN88US=> MVnTRW5ITVJ?
ES8 NV3EU3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ7ND6xPFIh|ryP M{f4e3NCVkeHUh?=
U-698-M NG\IR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXNdG9RUUN3ME2yPVgvOjR|IN88US=> NWXSdJlNW0GQR1XS
HEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTPTWM2OD1|MEmuNVQ6KM7:TR?= NVnUW4JQW0GQR1XS
KINGS-1 M1e1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\KUWlEPTB;M{GwMlY4PCEQvF2= MUfTRW5ITVJ?
KY821 NY\1dZBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTN|Nj61PVUh|ryP MkLQV2FPT0WU
MZ1-PC Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLJOY1SUUN3ME2zOFUvPjF6IN88US=> NVjqWo1PW0GQR1XS
LS-411N MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLKU2NSUUN3ME2zOVQvPjZizszN MYXTRW5ITVJ?
SIG-M5 NYfp[mhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq0PYk6UUN3ME2zOVkvPzh{IN88US=> MmPXV2FPT0WU
HT MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonJTWM2OD1|NkeuO|EyKM7:TR?= M1z4[XNCVkeHUh?=
HC-1 NUDkNm43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS1TWM2OD1|NkeuO|g4KM7:TR?= MXTTRW5ITVJ?
NCI-H1694 NGraNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGxTWM2OD1|N{KuPVM1KM7:TR?= NETvVWxUSU6JRWK=
BB65-RCC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTN5Nj6yOFUh|ryP M13zc3NCVkeHUh?=
HAL-01 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN5OT64N|gh|ryP NEWydGVUSU6JRWK=
ARH-77 M4HUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\tR25KSzVyPUO5OE4xODhizszN NFT0UWpUSU6JRWK=
MZ7-mel M2\IcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXTTWM2OD1|OUeuNlM{KM7:TR?= M2\heHNCVkeHUh?=
SIMA NXG0XZg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL3XJVKSzVyPUSwN{46OzNizszN NFvmfpZUSU6JRWK=
DG-75 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\yfHR6UUN3ME20NVUvPjl6IN88US=> MXHTRW5ITVJ?
HUTU-80 NV[1NXY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TUWWlEPTB;NEG5MlE5PSEQvF2= NILLVotUSU6JRWK=
KNS-42 NEXvVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvLTWM2OD12MkWuPFE2KM7:TR?= MlfSV2FPT0WU
SH-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL2NJpKSzVyPUSyO{42PjVizszN M1TnVnNCVkeHUh?=
L-540 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLkTWM2OD12M{GuNFMyKM7:TR?= MmrCV2FPT0WU
NB10 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHlTWM2OD12NEGuNlM1KM7:TR?= MVHTRW5ITVJ?
ES1 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPWZWdvUUN3ME20OVIvPzV|IN88US=> NV\mWGl1W0GQR1XS
KMOE-2 NX7ndpBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHro[XBKSzVyPUS1Ok44OTFizszN MYLTRW5ITVJ?
MC116 M1XmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH1c4RRUUN3ME20OVgvOTF4IN88US=> M1TIdnNCVkeHUh?=
RCC10RGB NFr6cpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHxTWM2OD12NkCuNFA2KM7:TR?= M2jwUnNCVkeHUh?=
RL95-2 M1vne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfMd3BKSzVyPUS2NE4zOzdizszN MV7TRW5ITVJ?
Raji M1f3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jNR2lEPTB;NE[4MlE1OyEQvF2= Mn3uV2FPT0WU
CAS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnFTWM2OD12N{KuNFc{KM7:TR?= MoHGV2FPT0WU
Calu-6 NVPITHBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom1TWM2OD12N{WuNlY2KM7:TR?= M373W3NCVkeHUh?=
KG-1 M4mxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq0TWM2OD12N{iuOFQh|ryP M3\ocnNCVkeHUh?=
LB771-HNC NFLOSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TsXmlEPTB;NEiyMlI{OiEQvF2= M4rLfnNCVkeHUh?=
ACN NXPjTmRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7I[2FKSzVyPUS5N{42QTlizszN MU\TRW5ITVJ?
KM12 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fSb2lEPTB;NEm2MlU5QSEQvF2= MUDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
in solvent
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID